MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-22-2025
IQVIA Holdings Accounts Receivables 2011-2026 | IQV
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables IQVIA Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.2 B | 3.38 B | 2.92 B | 2.55 B | 2.41 B | 2.58 B | 2.39 B | 1.99 B | 1.71 B | 1.17 B | 975 M | 924 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.38 B | 924 M | 2.18 B |
Quarterly Accounts Receivables IQVIA Holdings
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.34 B | 3.27 B | 3.2 B | 3.2 B | 3.26 B | 3.43 B | 3.38 B | 3.23 B | 3.14 B | 3.06 B | 2.92 B | 2.64 B | - | 2.62 B | 2.55 B | 2.33 B | 2.28 B | 2.36 B | 2.41 B | 2.41 B | 2.41 B | 2.41 B | 2.58 B | 2.58 B | 2.58 B | 2.58 B | 2.39 B | 2.39 B | 2.39 B | 2.39 B | 2.1 B | 2.1 B | 2.1 B | 2.1 B | 1.71 B | 1.71 B | 1.71 B | 1.71 B | 1.17 B | 1.17 B | 1.17 B | 1.17 B | 975 M | 975 M | 975 M | 975 M | 924 M | 924 M | 924 M | 924 M | 745 M | 745 M | 745 M | 745 M | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.43 B | 745 M | 2.08 B |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 22.72 | 1.59 % | $ 246 M |  China |
 |
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | USA |
 |
BioNano Genomics
BNGO
|
4.75 M | $ 1.6 | - | $ 2.03 M | USA |
 |
Castle Biosciences
CSTL
|
51.2 M | $ 40.03 | -1.43 % | $ 1.11 B | USA |
 |
Co-Diagnostics
CODX
|
304 K | $ 6.05 | 0.33 % | $ 178 M | USA |
 |
DarioHealth Corp.
DRIO
|
3.16 M | $ 12.31 | 1.52 % | $ 349 M |  Israel |
 |
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | USA |
 |
Fulgent Genetics
FLGT
|
69 M | $ 27.91 | -0.36 % | $ 844 M | USA |
 |
Danaher Corporation
DHR
|
3.54 B | $ 236.45 | 0.37 % | $ 173 B | USA |
 |
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | China |
 |
DexCom
DXCM
|
974 M | $ 67.5 | -3.71 % | $ 26.1 B | USA |
 |
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
249 M | $ 101.75 | 0.11 % | $ 18.9 B | USA |
 |
CareDx, Inc
CDNA
|
51.1 M | $ 17.67 | -6.51 % | $ 950 M | USA |
 |
Anixa Biosciences
ANIX
|
173 K | $ 3.32 | 1.22 % | $ 106 K | USA |
 |
Guardant Health
GH
|
110 M | $ 109.37 | -0.51 % | $ 13.4 B | USA |
 |
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
735 M | $ 147.43 | -1.81 % | $ 23.4 B | USA |
 |
Charles River Laboratories International
CRL
|
721 M | $ 216.58 | -0.32 % | $ 11.1 B | USA |
 |
Mettler-Toledo International
MTD
|
687 M | $ 1 476.11 | 0.4 % | $ 31.3 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
121 M | $ 6.51 | -1.89 % | $ 590 M | USA |
 |
National Research Corporation
NRC
|
12.4 M | $ 19.34 | 2.33 % | $ 475 M | USA |
 |
Natera
NTRA
|
244 M | $ 238.34 | -6.31 % | $ 23.5 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.3 B | $ 177.53 | -0.38 % | $ 19.7 B | USA |
|
Biodesix
BDSX
|
8.6 M | $ 5.85 | -1.85 % | $ 759 M | USA |
 |
OPKO Health
OPK
|
118 M | $ 1.36 | -0.37 % | $ 944 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.94 B | $ 254.89 | 0.48 % | $ 21.4 B | USA |
 |
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
1.34 B | $ 189.24 | -6.74 % | $ 15.6 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
474 M | $ 706.32 | -1.15 % | $ 58.2 B | USA |
 |
Lantheus Holdings
LNTH
|
321 M | $ 69.55 | 0.26 % | $ 4.81 B | USA |
 |
Agilent Technologies
A
|
1.17 B | $ 146.93 | -0.59 % | $ 44.7 B | USA |
 |
Biomerica
BMRA
|
731 K | $ 2.79 | 0.36 % | $ 6.41 M | USA |
 |
Bioventus
BVS
|
123 M | $ 7.77 | 2.04 % | $ 487 M | USA |